Live Breaking News & Updates on மருந்தகம் தரம் கூட்டணி
Stay updated with breaking news from மருந்தகம் தரம் கூட்டணி. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Alignment Healthcare Earns 2021 Excellence in Pharmacy Quality Award ORANGE, Calif., May 13, 2021 (GLOBE NEWSWIRE) Medicare Advantage company Alignment Healthcare, Inc., has been recognized for excellence in quality of its Medicare Advantage prescription drug (MAPD) plan, Alignment Health Plan (contract H3815), by the Pharmacy Quality Alliance (PQA) for the fourth consecutive year. The 2021 PQA Laura Cranston Excellence in Quality Award goes to MAPDs with at least a 4.5-star Part D summary rating and a perfect 5-star rating on all five PQA medication measures used in the Centers for Medicare & Medicaid Services (CMS) star ratings program. CMS evaluates Medicare plan quality every year based on a 5-star rating system. The award was announced today at PQA’s annual meeting. ....
Prime Therapeutics proactive prescriber outreach significantly improves statin use in Medicare members with diabetes Largest statin use improvement found when program is coupled with proactive pharmacist outreach News provided by Share this article Share this article EAGAN, Minn., May 11, 2021 /PRNewswire/ Using a proactive prescriber outreach program, Prime Therapeutics LLC (Prime), a pharmacy benefit manager (PBM) serving nearly 33 million members nationally, saw increased statin use in Medicare members with diabetes. According to the American Diabetes Association, 34.2 million Americans (10.5% of the population) have diabetes. 1 In the Medicare (age 65+) population, the prevalence is even higher at 26.8% of seniors. 1 Statin therapy is recommended for most adults with diabetes based on their cardiovascular risk. ....
Excelera to Present Poster on Tuberculosis Screening Compliance at PQA Annual Meeting Scale of Excelera Network and proprietary data platform leveraged to simplify real-world analysis of patient compliance with pre-treatment screenings prior to biologic therapy use News provided by Share this article Share this article MINNEAPOLIS, May 11, 2021 /PRNewswire/ Excelera®, a subsidiary of Shields Health Solutions and the company behind the Excelera Network, announced today that it will present a poster on tuberculosis (TB) screening compliance and the value of pharmacist interventions in supporting safe medication use at the Pharmacy Quality Alliance (PQA) Annual Meeting. Excelera s presentation was selected from a wide range of submissions and will be available for attendees to view throughout the Annual Meeting, which is being held virtually from May 11 to 13. The paper will be presented during the PQA Annual Meeting poster session, which is being held on Mon ....
Senior Editor Women with MS who continue their disease-modifying therapy, or DMT, throughout pregnancy have lower hospitalization costs and use, compared to those who discontinued their therapy. That finding comes from a retrospective study conducted by Walgreens in collaboration with AllianceRx Walgreens Prime to understand how non-adherence to these women’s DMTs would impact healthcare cost and utilization over a two-year period. The researchers presented the findings on Feb. 26 at the virtual Americas Committee for Treatment and Research in Multiple Sclerosis Forum 2021. MS is a chronic condition affecting the central nervous system that affects roughly 2.3 million people worldwide, with women affected two to three times as often as men. According to the National MS Society, none of the DMTs are approved for use during pregnancy yet discontinuing DMTs may cause relapse of disease. However, for certain DMTs, studies do indicate that some patients c ....
Share this article Share this article ORLANDO, Fla., March 1, 2021 /PRNewswire/ AllianceRx Walgreens Prime recently announced results from research analyzing data of females with multiple sclerosis (MS) who became pregnant, and the impact of adherence to their disease-modifying therapies (DMTs) on hospital utilization and cost. Researchers wanted to understand how non-adherence to their DMTs would impact healthcare cost and utilization over a two-year period. The findings suggest for those women continuing their therapy throughout pregnancy, hospitalization costs and use were lower, compared to those who discontinued their therapy. The retrospective study was conducted by Walgreens, in collaboration with AllianceRx Walgreens Prime, a leading specialty and home delivery pharmacy. ....